We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Immunocore Holdings PLC Sponsored ADR (IMCR) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Immunocore Holdings PLC Sponsored ADR (IMCR - Free Report) closed at $46.71, marking a -1.37% move from the previous day. This change lagged the S&P 500's daily gain of 0.56%. Meanwhile, the Dow gained 0.41%, and the Nasdaq, a tech-heavy index, added 1.35%.
Heading into today, shares of the company had lost 17.69% over the past month, lagging the Medical sector's loss of 2.2% and the S&P 500's loss of 1.48% in that time.
Investors will be hoping for strength from Immunocore Holdings PLC Sponsored ADR as it approaches its next earnings release. On that day, Immunocore Holdings PLC Sponsored ADR is projected to report earnings of -$0.28 per share, which would represent year-over-year growth of 41.67%. Our most recent consensus estimate is calling for quarterly revenue of $47.92 million, up 62.1% from the year-ago period.
IMCR's full-year Zacks Consensus Estimates are calling for earnings of -$1.18 per share and revenue of $210.5 million. These results would represent year-over-year changes of -8.26% and +20.26%, respectively.
It is also important to note the recent changes to analyst estimates for Immunocore Holdings PLC Sponsored ADR. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 77.9% lower. Immunocore Holdings PLC Sponsored ADR is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 88, putting it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Immunocore Holdings PLC Sponsored ADR (IMCR) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Immunocore Holdings PLC Sponsored ADR (IMCR - Free Report) closed at $46.71, marking a -1.37% move from the previous day. This change lagged the S&P 500's daily gain of 0.56%. Meanwhile, the Dow gained 0.41%, and the Nasdaq, a tech-heavy index, added 1.35%.
Heading into today, shares of the company had lost 17.69% over the past month, lagging the Medical sector's loss of 2.2% and the S&P 500's loss of 1.48% in that time.
Investors will be hoping for strength from Immunocore Holdings PLC Sponsored ADR as it approaches its next earnings release. On that day, Immunocore Holdings PLC Sponsored ADR is projected to report earnings of -$0.28 per share, which would represent year-over-year growth of 41.67%. Our most recent consensus estimate is calling for quarterly revenue of $47.92 million, up 62.1% from the year-ago period.
IMCR's full-year Zacks Consensus Estimates are calling for earnings of -$1.18 per share and revenue of $210.5 million. These results would represent year-over-year changes of -8.26% and +20.26%, respectively.
It is also important to note the recent changes to analyst estimates for Immunocore Holdings PLC Sponsored ADR. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 77.9% lower. Immunocore Holdings PLC Sponsored ADR is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 88, putting it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.